Loading
Latest filing published 22 Aug 2023 for Timber Pharmaceuticals, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
John Koconis, listed as chief executive, appears in our data through filings on Timber Pharmaceuticals, Inc. shares, published by SEC (Form 4). The record holds 2 filings, for trades running from 15 December 2021 to 20 August 2023.
Purchases make up the whole of the open-market record (1 purchase, €6,825). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant.
On 22 August 2023 came the latest disclosure, a share grant in Timber Pharmaceuticals, Inc. The last purchase on record was published on 16 December 2021, which is 1,773 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations